AF
CRSP icon

Advisornet Financial’s CRISPR Therapeutics CRSP Stock Holding History

Advisornet Financial’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$464K Buy
8,503
+500
+6% +$26.4K 0.02% 435
2026
Q1 		$381K Buy
8,003
+1,111
+16% +$58.6K 0.02% 446
2025
Q4 		$361K Buy
6,892
+58
+0.8% +$3.47K 0.02% 463
2025
Q3 		$443K Buy
6,834
+701
+11% +$40.2K 0.03% 406
2025
Q2 		$298K Buy
6,133
+1,060
+21% +$41K 0.02% 481
2025
Q1 		$173K Buy
5,073
+2,595
+105% +$110K 0.01% 584
2024
Q4 		$97.5K Buy
2,478
+1,181
+91% +$55.8K 0.01% 696
2024
Q3 		$60.9K Buy
1,297
+197
+18% +$10K ﹤0.01% 846
2024
Q2 		$59.4K Sell
1,100
-60
-5% -$3.47K 0.01% 765
2024
Q1 		$79.1K Buy
1,160
+135
+13% +$9.66K 0.01% 694
2023
Q4 		$64.2K Hold
1,025
– – 0.01% 747
2023
Q3 		$46.5K Sell
1,025
-250
-20% -$12.9K ﹤0.01% 803
2023
Q2 		$71.6K Buy
1,275
+750
+143% +$42.6K 0.01% 724
2023
Q1 		$23.7K Hold
525
– – ﹤0.01% 1019
2022
Q4 		$21.3K Sell
525
-2
-0.4% -$106 ﹤0.01% 1036
2022
Q3 		$34K Hold
527
– – ﹤0.01% 961
2022
Q2 		$32K Sell
527
-33
-6% -$1.94K ﹤0.01% 996
2022
Q1 		$35K Buy
560
+25
+5% +$1.57K ﹤0.01% 1077
2021
Q4 		$41K Sell
535
-490
-48% -$42.8K ﹤0.01% 1074
2021
Q3 		$115K Buy
1,025
+13
+1% +$1.63K 0.01% 740
2021
Q2 		$164K Hold
1,012
– – 0.01% 646
2021
Q1 		$123K Buy
1,012
+960
+1,846% +$145K 0.01% 689
2020
Q4 		$8K Buy
52
+50
+2,500% +$5.91K ﹤0.01% 1334
2020
Q3 		$0 Hold
2
– – ﹤0.01% 1744
2020
Q2 		$0 Buy
+2
New +$117 ﹤0.01% 1793

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Advisornet Financial's CRSP Position: Q2 2026 in Review

Advisornet Financial increased its CRISPR Therapeutics (CRSP) stake by 6.2% in Q2 2026, buying an estimated $26.4K and bringing the position to 8,503 shares worth $464K. The position accounts for 0.02% of the portfolio, ranked #435.

Advisornet Financial first reported a position in CRSP in Q2 2020 and has held it in 25 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Advisornet Financial held 8,503 shares of CRISPR Therapeutics worth $464K as of Q2 2026.
  • Advisornet Financial bought 500 CRISPR Therapeutics shares in Q2 2026, an estimated $26.4K.
  • CRISPR Therapeutics made up 0.02% of Advisornet Financial's portfolio in Q2 2026, its #435 holding.
  • Advisornet Financial first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.